Botulinum strain is not trade secret: U.S. ITC reasons in Daewoong vs Medytox case

Kim Si-gyun and Lee Eun-joo 입력 2021. 1. 14. 13:00
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

South Korean drugmaker Daewoong Pharmaceutical Co. received much lighter-than-expected 21-month sanction on sales of its botulinum products in the United States from the International Trade Commission (ITC) last month because although it was found to have copied the manufacturing process of a botulinum toxin strain of its rival Medytox Inc., the strain itself does not qualify as a “trade secret.”

“The genetic evidence establishes by more than a preponderance of the evidence that Daewoong derived its strain from Medytox,” the ITC said in its entire 74-page opinion released on Wednesday elaborating on the grounds for its December ruling.

“Complainants [however] failed to satisfy their burden to establish that the Medytox strain or its genetic makeup quality as a trade secret.”

The U.S. trade panel on Dec. 16 ordered a 21-month ban on imports of Daewoong Pharmaceutical’s botulinum products into the U.S. – down from the initial 10-year ban proposed by the preliminary panel that said Daewoong Pharmaceutical misappropriated trade secrets that belong to Medytox.

Daewoong Pharmaceutical and Medytox are both manufacturers of botulinum toxin or botox products that are widely used to treat wrinkles.

In 2019, Medytox filed a complaint with the ITC, saying that Daewoong Pharmaceutical stole trade secrets of the manufacturing process and introduced its botox product in the U.S.

Daewoong Pharmaceutical see the latest release has put to an end the long dispute between the two companies over botulinum strain origin.

Daewoong Pharmaceutical still plans to make an appeal with the federal appellate court over the decision that it infringed manufacturing processing technology.

An unnamed official from Daewoong Pharmaceutical said that it has sufficient evidence that it independently developed processing technology of botulinum strain and that Medytox manufacturing process is a generally-used technology from several decades ago and is different from its own.

Medytox expressed regret that the botulinum strain was not taken as trade secret, but still focused on how illegal activity was involved.

The Korea Centers for Disease Control, meanwhile, plans to inspect all local botulinum toxin manufacturers in Korea amid growing controversy over safety and origin of botulinum strain.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?